Oral ACTH Blocker Safely Reduces Cortisol, Early Data Show

Oral ACTH Blocker Safely Reduces Cortisol, Early Data Show

302814

Oral ACTH Blocker Safely Reduces Cortisol, Early Data Show

CRN04894, a first-in-class, investigational oral medication to treat Cushing’s disease, demonstrated pharmacologic proof-of-concept with a dose-dependent suppression of cortisol, according to data from a Phase 1 study. CRN04894, developed by Crinetics Pharmaceuticals, is designed to block the interaction (antagonist) between the MC2R receptor, found specifically on the adrenal glands, and adrenocorticotropic hormone (ACTH), which is secreted in excess typically due to a non-cancerous tumor in the brain’s pituitary gland. High levels of ACTH signal the…

You must be logged in to read/download the full post.